<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aspira Pathlab & Diagnostics has submitted its annual disclosure to BSE confirming it is not classified as a 'Large Corporate' as of March 31, 2025, under SEBI's November 2018 circular on debt securities fundraising by large entities. The Annexure A filed with the exchange shows the company has Nil outstanding borrowings and no credit rating assigned for the previous financial year. BSE Limited is named as the stock exchange where any shortfall-related fine would be payable, though no such fine applies here. The letter is signed by the CFO Balkrishna Talawadekar and Company Secretary Krupali Shah. This is a routine annual compliance submission required from all listed companies under the SEBI framework.
No material impact on shareholders — this is a standard regulatory compliance filing. The Nil borrowings suggest Aspira Pathlab is currently a debt-free company on its books.